ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Pharmasset Nominates PSI-7851 As A Lead Development Candidate For The Treatment Of Chronic Hepatitis C
Pharmasset, Inc.
(Nasdaq: VRUS) has nominated PSI-7851 as a lead development candidate for
the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary
nucleotide analogue polymerase inhibitor of HCV that is being advanced into
Good Laboratory Practice (GLP) animal toxicity studies required for
submission of an Investigational New Drug (IND) application with the FDA or
an equivalent foreign regulatory filing. PSI-7851 has demonstrated in vitro
potency that is approximately 15- to 20-fold greater than the in vitro
potency of R7128, a nucleoside analog polymerase inhibitor of HCV that
Pharmasset is developing through its collaboration with Roche.
"Our in-house research team has, once again, discovered a new potential
product candidate for the treatment of chronic HCV," stated Dr. Michael
Otto, Pharmasset's Chief Scientific Officer. "Our goal continues to be the
identification of anti-HCV compounds with improved potency, equivalent or
improved safety and oral bioavailability. In addition, we have focused on
increasing intrahepatic triphosphate levels, which may lead to a higher
level of active drug in the liver. We anticipate completing the required
animal toxicity studies and filing an IND in the first quarter of 2009."
Nucleotide analogs have shown the ability to deliver higher levels of
the active triphosphate form of the drug into infected cells. PSI-7851 has
demonstrated in vitro anti-HCV activity with EC90 values of 0.31 +/- 0.12
uM, which is approximately 15- to 20-fold more potent than the active
metabolite of R7128, PSI-6130. In vitro studies of PSI-7851 have not shown
evidence of any mitochondrial or other cellular toxicities that may be
associated with some nucleoside analogs. The half-life of the triphosphate
in primary human hepatocytes is approximately 38 hours, which suggests the
possibility for once-daily dosing. Early animal studies indicate that
PSI-7851 can achieve concentrations of active triphosphate in the liver of
up to 1,000 times higher than PSI-6130 at equivalent doses.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C
virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, is in a 4-week Phase 1
clinical trial in combination with Pegasys(R) plus Copegus(R) through a
strategic collaboration with Roche. Racivir, which is being developed for
the treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation the risk
that our results from early studies with PSI-7851 are not repeated in
future studies, the risk that we are not able to gather the data and
information necessary to, or that we otherwise cannot, file an IND for
PSI-7851, the risk that PSI-7851 never becomes a product candidate or is
never successfully developed and commercialized, the risk that adverse
events could cause the cessation or delay of any of the ongoing or planned
clinical trials and/or our development of any or all of our product
candidates, the risk that we cannot enroll enough patients for the Phase 3
registration studies for clevudine, the risk that our collaboration with
Roche will not continue or will not be successful, the risk that any one or
more of our product candidates will not be successfully developed and
commercialized and the risk that we will not be able to further develop any
of the compounds from the new series of anti-HCV molecules currently being
investigated by us. For a discussion of these risks and uncertainties, any
of which could cause our actual results to differ from those contained in
the forward-looking statements, see the section of our Annual Report on
Form 10-K for the fiscal year ended September 30, 2007 filed with the
Securities and Exchange Commission entitled "Risk Factors" and discussions
of potential risks and uncertainties in our subsequent filings with the
Securities and Exchange Commission.
Pharmasset, Inc.
http://www.pharmasset.com
View drug information on Pegasys.
Pharmasset nominalizeazã PSI-7851 Ca lider de Dezvoltare candidate pentru tratamentul hepatitei cronice C - Pharmasset Nominates PSI-7851 As A Lead Development Candidate For The Treatment Of Chronic Hepatitis C - articole medicale engleza - startsanatate